Login    Join free Add to favorites    中文
home > news > CEVEC Pharmaceuticals Signs License Agreement with Yuhan Corporation of South Korea
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
CEVEC Pharmaceuticals Signs License Agreement with Yuhan Corporation of South Korea

hits:1056     Date:12/20/12
Cologne, Germany, December 20, 2012 / B3C newswire / - CEVEC Pharmaceuticals (鈥淐EVEC鈥), the developer of a novel human expression system derived from amniocytes, and Yuhan Corporation (鈥淵uhan鈥), a leading manufacturer of pharmaceutical products based in Seoul, South Korea announced today the signing of a CAP-Technology license agreement. The license will enable Yuhan to utilize CEVEC鈥檚 CAP-T™ and CAP® cell expression systems for the production and development of various therapeutic proteins.
CAP-T™ CAP® cells are immortalized cell lines for transient and stable protein production developed by CEVEC. These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture and show post-translational modifications that are human-like, including authentic human glycosylation patterns. The Technology allows for superior protein yields in a shorter time frame than traditional methods.
鈥淲ith Yuhan Corporation we have won one of the most prestigious Asian Pharma Companies as a customer. We鈥檙e very pleased that Yuhan has chosen our CAP and CAP-T expression sytems as a pivotal platform to develop therapeutically relevant molecules. I鈥檓 convinced that the cells will have a major impact to develop more efficient biologics and will also shorten the timeline to enter clinical phases 鈥 stated Wolfgang Kintzel, CEO at CEVEC. 
Dr. Jong-Gyun Kim, Head of the Bio-Innovation Unit at Yuhan Research Institute said: 鈥淎fter evaluating CAP and CAP-T we are excited about the potential of CEVEC鈥檚 CAP Technology. We obtained outstanding results from transfections of various target proteins in CAP-cells and we are convinced that this expression system with it鈥檚 authentic human glycosylation profile will be of great benefit to further develop our pipeline molecules"
About CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH, operational since 2004 and located in Cologne, Germany, is a biopharmaceutical company that specializes in developing and producing therapeutic proteins, vaccines and monoclonal antibodies with human glycosylation patterns. CEVEC's novel proprietary and patent-protected human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules and various vaccines. CEVEC is licensing out its human cell-based expression platform as well as its own biobetter candidates through partnerships with renowned pharmaceutical and biotech companies.
About Yuhan
Yuhan Corporation, the leading pharmaceutical company in South Korea, is focusing its R&D capabilities on new chemical entities, new biologics, herbal medicines, and APIs for global markets. For the last 86 years, Yuhan is committed to deliver advanced and innovative medicines with a slogan 鈥淚nnovative, Nimble, and Translational R&D鈥. In 2007, 鈥楻evanex鈥, the world鈥檚 first acid pump agonist was out-licensing to China, and is now supplied world-wide to markets in Asia. Yuhan is to become the global premiere customer-focused pharma company with value driven, globally competitive R&D capability.

Wolfgang Kintzel, CEO
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln, Germany
fon +49 (0) 221-46 02 08 鈥 00
fax +49 (0) 221-46 02 08 鈥 01
Jong-Gyun Kim, Ph.D.
Head, BioInnovation Unit, Yuhan Corporation
416-1 Gongse-dong, Yongin-si, Korea
Tel +82 31-899-4168
Fax +82 31-275-6145
Related News>> more

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙